DaVita Inc. is a healthcare provider specializing in kidney care and dialysis services, primarily serving patients suffering from end-stage renal disease (ESRD) and chronic kidney failure. The company's core business model revolves around operating a network of outpatient dialysis centers, where patients undergo life-sustaining hemodialysis treatments. DaVita operates over 2,600 outpatient dialysis centers in the United States, alongside hundreds of centers across more than a dozen other countries.
Revenue is predominantly generated through patient service fees for dialysis treatments and the administration of related pharmaceuticals. In recent periods, U.S. dialysis services have accounted for approximately 86% of total revenues. The company relies heavily on government-based health insurance programs, such as Medicare and Medicaid, which cover the majority of its patients. However, commercial payers, while representing a smaller portion of the patient base and revenue, generate a disproportionate share of the company's profits due to higher reimbursement rates.
Beyond its core U.S. dialysis operations, DaVita's ancillary services segment includes international dialysis operations, integrated kidney care, disease management services, and clinical research programs. The company also operates clinical laboratories that provide routine and specialized testing for ESRD patients. DaVita's competitive position is supported by its large geographic footprint, integrated care models, and operational scale in a highly regulated and capital-intensive industry.
